Cellulitis is an acute, spreading, non-purulent bacterial infection of the dermis and subcutaneous tissue.
Recognition of Cellulitis's full clinical spectrum improves diagnostic accuracy and therapeutic response.
Epidemiology and Clinical Significance
Cellulitis demonstrates distinct epidemiological patterns across different demographic groups and geographic regions.
- Factor 1: Most commonly Group A Streptococcus (GAS)
- Factor 2: Staphylococcus aureus increasingly common
- Factor 3: Entry through breaks in skin barrier
- Factor 4: Risk factors: diabetes, venous insufficiency, lymphedema, immunosuppression
Causes and Risk Factors
Cellulitis develops through dysregulation of normal skin homeostatic mechanisms.
- Erythema with poorly demarcated borders
- Warmth and edema
- Pain and tenderness
- Systemic symptoms (fever, chills, malaise)
- Rapid progression if untreated
Pathophysiology and Disease Mechanisms
The pathophysiology of Cellulitis involves multiple interconnected biological pathways.
- Beta-lactam antibiotics (penicillin, amoxicillin-clavulanate) - first-line
- Cephalosporins for penicillin-allergic patients
- MRSA coverage if risk factors present
- Elevated limb and compression
- Hospitalization if extensive, facial involvement, or systemic toxicity
- Search for and treat underlying cause
Symptoms and Clinical Presentation
Symptom progression in Cellulitis correlates with underlying pathophysiological changes.
Diagnostic Approach and Clinical Assessment
Patients with Cellulitis present with diverse clinical phenotypes ranging from mild to severe.
Treatment Approaches and Therapeutic Options
First-line therapies for Cellulitis have established efficacy and favorable safety profiles.
When to Seek Professional Dermatological Care
First-line therapies for Cellulitis have established efficacy and favorable safety profiles.
Prognosis and Outcome
Long-term outcomes in Cellulitis are favorable when management is optimized and monitored regularly.
Living with This Condition: Patient Support and Resources
First-line therapies for Cellulitis have established efficacy and favorable safety profiles.
Conclusion and Key Takeaways
Emerging therapies for Cellulitis target specific pathophysiological mechanisms.
Conclusion
First-line therapies for Cellulitis have established efficacy and favorable safety profiles.
Conclusion
Comprehensive management of Cellulitis integrates clinical expertise with patient education and shared decision-making. Early intervention prevents complications and optimizes long-term outcomes. Dermatologists can provide personalized treatment plans tailored to individual disease manifestations.